Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humans
- PMID: 21289073
- DOI: 10.1124/dmd.110.037341
Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humans
Abstract
Brivanib [(R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[1,2,4]triazin-6-yloxy)propan-2-ol, BMS-540215] is a potent and selective dual inhibitor of vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) signaling pathways. Its alanine prodrug, brivanib alaninate [(1R,2S)-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methylethyl ester, BMS-582664], is currently under development as an oral agent for the treatment of cancer. This study describes the in vivo biotransformation of brivanib after a single oral dose of [(14)C]brivanib alaninate to intact rats, bile duct-cannulated (BDC) rats, intact monkeys, BDC monkeys, and humans. Fecal excretion was the primary route of elimination of drug-derived radioactivity in animals and humans. In BDC rats and monkeys, the majority of radioactivity was excreted in bile. Brivanib alaninate was rapidly and completely converted via hydrolysis to brivanib in vivo. The area under the curve from zero to infinity of brivanib accounted for 14.2 to 54.3% of circulating radioactivity in plasma in animals and humans, suggesting that metabolites contributed significantly to the total drug-related radioactivity. In plasma from animals and humans, brivanib was a prominent circulating component. All the metabolites that humans were exposed to were also present in toxicological species. On the basis of metabolite exposure and activity against VEGF and FGF receptors of the prominent human circulating metabolites, only brivanib is expected to contribute to the pharmacological effects in humans. Unchanged brivanib was not detected in urine or bile samples, suggesting that metabolic clearance was the primary route of elimination. The primary metabolic pathways were oxidative and conjugative metabolism of brivanib.
Similar articles
-
Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.Cancer Chemother Pharmacol. 2009 Dec;65(1):55-66. doi: 10.1007/s00280-009-1002-0. Epub 2009 Apr 26. Cancer Chemother Pharmacol. 2009. PMID: 19396600
-
Metabolic chiral inversion of brivanib and its relevance to safety and pharmacology.Drug Metab Dispos. 2012 Dec;40(12):2374-80. doi: 10.1124/dmd.112.047340. Epub 2012 Sep 14. Drug Metab Dispos. 2012. PMID: 22983304
-
Metabolism and disposition of [14C]BMS-690514 after oral administration to rats, rabbits, and dogs.Drug Metab Dispos. 2010 Jul;38(7):1189-201. doi: 10.1124/dmd.110.032755. Epub 2010 Apr 2. Drug Metab Dispos. 2010. PMID: 20363952
-
Brivanib alaninate for cancer.Expert Opin Investig Drugs. 2011 Apr;20(4):577-86. doi: 10.1517/13543784.2011.565329. Epub 2011 Mar 11. Expert Opin Investig Drugs. 2011. PMID: 21391890 Review.
-
Brivanib, a novel dual VEGF-R2/bFGF-R inhibitor.Anticancer Res. 2010 Nov;30(11):4477-83. Anticancer Res. 2010. PMID: 21115896 Review.
Cited by
-
Amino Acids in the Development of Prodrugs.Molecules. 2018 Sep 11;23(9):2318. doi: 10.3390/molecules23092318. Molecules. 2018. PMID: 30208629 Free PMC article. Review.
-
Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors.Clin Pharmacokinet. 2016 Jan;55(1):47-77. doi: 10.1007/s40262-015-0302-2. Clin Pharmacokinet. 2016. PMID: 26201307 Review.
-
Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.Target Oncol. 2012 Sep;7(3):173-81. doi: 10.1007/s11523-012-0229-6. Epub 2012 Aug 25. Target Oncol. 2012. PMID: 22923165 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Chemical Information
